Biogen Inc

* Biogen's Investigational Alzheimer's Disease TreatmentAducanumab Accepted Into European Medicines Agency's PrimeProgram

* Through Prime Program Biogen Will Have Access To EnhancedSupport From EMASource text for Eikon: Further company coverage:



http://feeds.reuters.com/~r/reuters/.../idUSFWN18T0KQ